Chunkit Fung is an Oncology physician affiliated with University of Rochester Medical Center. OpenAlex indexes 229 publications with 4,316 citations (h-index 33); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
601 Elmwood Avenue
Rochester, NY 146420001
Telephone
585-275-5823Registry record last updated 6 Jul 2023.
Clinical trials
- Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
Sponsor: University of Rochester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.8%Androgen Receptor Inhibitor45%Xtandi67%Bicalutamide33%Part D≥13 patientsAnti-androgens13.3%Erleada100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
16.7%Corticosteroid16.7%Prednisone100%Part D<11 patientsNervous system
12.5%Phenothiazine12.5%Prochlorperazine Maleate100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy
Journal of Clinical Oncology
2023 - Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship
Journal of Clinical Oncology
2023 - Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ann Falsey, MD
University of Rochester Medical Center
Louis Constine, MD
University of Rochester Medical Center
Supriya Mohile, MD
University of Rochester Medical Center
Edward Messing, MD
University of Rochester Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”